AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10091954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7575861 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal and postnatal support groups
Number of subjects: 129
Study 7575861 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 15374489 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicergoline
Number of subjects: 12
Study 15374489 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nicergoline
Number of subjects: 12
Study 15374489 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg co-dergocrine mesylate (CDM)
Number of subjects: 12
Study 15374489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 37863 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg i.v.
Number of subjects: 90
Study 37863 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg i.v.
Number of subjects: 90
Study 31755550 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 160
Study 31755550 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet counseling
Number of subjects: 160
Study 31755550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined AE + DASH
Number of subjects: 160
Study 31755550 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE) controls
Number of subjects: 160
Study 31755550 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise groups
Number of subjects: 160
Study 31755550 — intervention group
Group type: COMPARATOR
Intervention: Non-DASH participants
Number of subjects: 160
Study 31755550 — intervention group
Group type: COMPARATOR
Intervention: Non-Exercise participants
Number of subjects: 160
Study 30290018 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.33% gel once a day for 4 days
Number of subjects: 37
Study 27527199 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interactions about e-cigarettes
Number of subjects: 2149
Study 27527199 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations to use e-cigarettes
Number of subjects: 2149
Study 27527199 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for recommending e-cigarettes
Number of subjects: 2149
Study 27527199 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with recommending e-cigarettes for health reasons
Number of subjects: 2149
Study 24164733 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 177
Study 24164733 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 177
Study 24164733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 177
Study 24164733 — intervention group
Group type: COMPARATOR
Intervention: Galantamine
Number of subjects: 177
Study 24321716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined and resistance exercise
Number of subjects: 28
Study 24321716 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 28
Study 24321716 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 28
Study 20966319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute iohexol (Omnipaque)
Number of subjects: 300
Study 20966319 — intervention group
Group type: COMPARATOR
Intervention: Dilute diatrizoate sodium (Gastroview)
Number of subjects: 300
Study 20966319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 300
Study 18212336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention challenging the legitimacy of the sociocultural norm
Number of subjects: 0
Study 18212336 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16573705 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg once daily
Number of subjects: 1974
Study 16573705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1974
Study 14602740 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (TGZ) 150 mg/d
Number of subjects: 398
Study 14602740 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (TGZ) 300 mg/d
Number of subjects: 398
Study 14602740 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (TGZ) 600 mg/d
Number of subjects: 398
Study 14602740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 10849246 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-oesophageal probe
Number of subjects: 35
Study 8785074 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 104
Study 8785074 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 104
Study 1860284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (3 times daily for 7 days)
Number of subjects: 10
Study 1860284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times daily for 7 days)
Number of subjects: 10
Study 6802408 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg single oral dose)
Number of subjects: 10
Study 6802408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30583953 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable mixed H∞ and passive control under adaptive event-triggered scheme
Number of subjects: 0
Study 30583953 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive event-triggered scheme
Number of subjects: 0
Study 29394491 — intervention group
Group type: EXPERIMENTAL
Intervention: l-citrulline (6 g/day)
Number of subjects: 26
Study 29394491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 27244859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P)
Number of subjects: 3147
Study 27244859 — intervention group
Group type: COMPARATOR
Intervention: Quality Improvement Technical Support (QITS)
Number of subjects: 3147
Study 24969056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (200 mg, 2 tablets bid, for 7 days monthly for 12 months) and probiotic VSL#3 (450 × 10(9) FU per day)
Number of subjects: 106
Study 24969056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin and VSL#3
Number of subjects: 106
Study 24969056 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 106
Study 22574799 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy (DBT)
Number of subjects: 42
Study 22574799 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 42
Study 21062838 — intervention group
Group type: EXPERIMENTAL
Intervention: HEIA intervention programme (12 schools)
Number of subjects: 114
Study 21062838 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 schools)
Number of subjects: 114
Study 18674402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 79
Study 18674402 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 79
Study 15831901 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 19
Study 15831901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12856483 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased digoxin synthesis, decreased membrane Na(+)‐K+ ATPase activity, increased tryptophan catabolites (serotonin, quinolinic acid, and nicotine), decreased tyrosine catabolites (dopamine, noradrenaline, and morphine) in creative individuals; correlated with right hemispheric dominance.
Number of subjects: 0
Study 12856483 — intervention group
Group type: COMPARATOR
Intervention: Decreased digoxin synthesis, increased membrane Na(+)‐K+ ATPase activity, decreased tryptophan catabolites (serotonin, quinolinic acid, and nicotine), increased tyrosine catabolites (dopamine, noradrenaline, and morphine) in non-creative individuals; correlated with left hemispheric dominance.
Number of subjects: 0
Study 10680108 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (LMA removed when signs of rejection observed)
Number of subjects: 63
Study 10680108 — intervention group
Group type: COMPARATOR
Intervention: Group B (LMA removed when patient could open mouth on command)
Number of subjects: 63
Study 10680108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 8988452 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg/day + Pindolol 7.5 mg/day
Number of subjects: 33
Study 8988452 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg/day + Fluoxetine 20 mg/day
Number of subjects: 33
Study 8988452 — intervention group
Group type: COMPARATOR
Intervention: Trazodone 100 mg/day + Placebo
Number of subjects: 33
Study 1361935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 15
Study 1361935 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg daily
Number of subjects: 15
Study 1361935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 15
Study 1361935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6439565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal disodium chromoglycate
Number of subjects: 13
Study 6439565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31932571 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills development program based on Gardner's Multiple Intelligence Theory
Number of subjects: 67
Study 31932571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 67
Study 29156378 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training therapy using Lokomat®Pediatric, 20 sessions
Number of subjects: 30
Study 29156378 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no sessions of Lokomat®Pediatric)
Number of subjects: 30
Study 26399905 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive approach presenting calculated risks of postoperative nausea and vomiting (PONV) to physicians.
Number of subjects: 57
Study 26399905 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 57
Study 24201706 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 steps/day
Number of subjects: 0
Study 24201706 — intervention group
Group type: COMPARATOR
Intervention: 1,500 steps/day
Number of subjects: 0
Study 23144467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 216
Study 20229018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic intervention (75 min at simulated altitude of 2,980 m)
Number of subjects: 12
Study 20229018 — intervention group
Group type: COMPARATOR
Intervention: Control values (trial day one)
Number of subjects: 12
Study 18561722 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day purified omega-3 fatty acids
Number of subjects: 50
Study 18561722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15757934 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for Alzheimer's disease (APOE genotype disclosure)
Number of subjects: 148
Study 15757934 — intervention group
Group type: COMPARATOR
Intervention: No genetic testing (Control group)
Number of subjects: 148
Study 11803070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5ml (15.5 microg of each HA antigen) dose of the trivalent inactivated influenza vaccine
Number of subjects: 0
Study 11803070 — intervention group
Group type: COMPARATOR
Intervention: 0.25ml (7.75 microg of each HA antigen) dose of the trivalent inactivated influenza vaccine
Number of subjects: 0
Study 10357750 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vitamin E
Number of subjects: 161
Study 10357750 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vitamin E
Number of subjects: 161
Study 10357750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 7948266 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (glucose polymer) used in peritoneal dialysis
Number of subjects: 0
Study 7948266 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated peritoneal dialysis regimens with icodextrin
Number of subjects: 0
Study 3127028 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (Premarin, 1.25 mg/day)
Number of subjects: 21
Study 31954575 — intervention group
Group type: EXPERIMENTAL
Intervention: High starch textured starter (45% starch) blended with 5% chopped hay fed free choice
Number of subjects: 96
Study 31954575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low starch pelleted starter (8% starch) fed at a rate up to 2.3 kg of dry matter (DM)/d with free‐choice long grass hay
Number of subjects: 96
Study 31954575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum access to a blend of 95% high starch textured starter (42% starch) and 5% chopped grass hay
Number of subjects: 96
Study 31954575 — intervention group
Group type: COMPARATOR
Intervention: High starch textured starter fed up to 2.7 kg of DM/d with free-choice long grass hay
Number of subjects: 96
Study 30610781 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant paclitaxel plus gemcitabine (6 cycles)
Number of subjects: 66
Study 30610781 — intervention group
Group type: COMPARATOR
Intervention: Sequential paclitaxel followed by gemcitabine (4 cycles each)
Number of subjects: 66
Study 28515196 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behaviour therapy (ICBT) for 12 weeks
Number of subjects: 67
Study 28515196 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behaviour therapy (ICBT)
Number of subjects: 67
Study 28515196 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 67
Study 25069908 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen
Number of subjects: 42
Study 25069908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25069908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 42
Study 22763161 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 25 (LM25)
Number of subjects: 193
Study 22763161 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin glargine (GL)
Number of subjects: 193
Study 22763161 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 193
Study 19717480 — intervention group
Group type: EXPERIMENTAL
Intervention: P(ET,CO(2)) >or=36 mmHg
Number of subjects: 298
Study 19717480 — intervention group
Group type: EXPERIMENTAL
Intervention: P(ET,CO(2)) in patients with PE
Number of subjects: 298
Study 19717480 — intervention group
Group type: COMPARATOR
Intervention: P(ET,CO(2)) in patients without PE
Number of subjects: 298
Study 19717480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of P(ET,CO(2)) >or=36 mmHg with Wells score <4
Number of subjects: 298
Study 17267222 — intervention group
Group type: COMPARATOR
Intervention: Control foot orthotics (n=10)
Number of subjects: 40
Study 17267222 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid foot orthotics (n=10)
Number of subjects: 40
Study 17267222 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimple foot orthotics (n=10)
Number of subjects: 40
Study 17267222 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain foot orthotics (n=10)
Number of subjects: 40
Study 17267222 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (Control, Grid, Dimple, Plain)
Number of subjects: 40
Study 15966880 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit full-mouth ultrasonic debridement with povidone iodine
Number of subjects: 36
Study 15966880 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit full-mouth ultrasonic debridement with water
Number of subjects: 36
Study 15966880 — intervention group
Group type: COMPARATOR
Intervention: Quadrant-wise ultrasonic debridement
Number of subjects: 36
Study 12204666 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with a three-field technique (35% of cases)
Number of subjects: 60
Study 12204666 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with a four-field pelvic box technique (65% of cases)
Number of subjects: 60
Study 12204666 — intervention group
Group type: EXPERIMENTAL
Intervention: Total radiation dose of 44.7 Gy with a standard deviation of 4.6 Gy
Number of subjects: 60
Study 12204666 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical target volume (CTV) drawn on CT scan
Number of subjects: 60
Study 12204666 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations provided during the trial
Number of subjects: 60
Study 11379854 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% amino acid‐based PD solution buffered with bicarbonate (Amino/Bic)
Number of subjects: 10
Study 11379854 — intervention group
Group type: COMPARATOR
Intervention: 1.5% glucose anhydrous‐containing bicarbonate‐buffered solution (Glu/Bic)
Number of subjects: 10
Study 11379854 — intervention group
Group type: COMPARATOR
Intervention: 1.5% glucose anhydrous‐based dialysis solution with lactate (Glu/Lac)
Number of subjects: 10
Study 8842579 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved metabolic control
Number of subjects: 35
Study 1505090 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sodium alginate (Kaltostat)
Number of subjects: 0
Study 1505090 — intervention group
Group type: COMPARATOR
Intervention: Trousered paraffin gauze
Number of subjects: 0
Study 1505090 — intervention group
Group type: COMPARATOR
Intervention: Glove finger packs
Number of subjects: 0
Study 1505090 — intervention group
Group type: EXPERIMENTAL
Intervention: All packing materials
Number of subjects: 0
Study 6489417 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 2.5 g
Number of subjects: 6
Study 6489417 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 10 g
Number of subjects: 6
Study 6489417 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g
Number of subjects: 6
Study 6489417 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 50 g
Number of subjects: 6
Study 6489417 — intervention group
Group type: COMPARATOR
Intervention: Water 300 ml only
Number of subjects: 6
Study 31345985 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective learning framework and toolkit for healthcare staff
Number of subjects: 0
Study 31345985 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous patient and relative survey and annual staff survey
Number of subjects: 0
Study 31345985 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated iterative co-design process
Number of subjects: 0
Study 31345985 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-adaptable workplace-based toolkit
Number of subjects: 0
Study 31345985 — intervention group
Group type: EXPERIMENTAL
Intervention: National cluster randomised step-wedge trial of the toolkit
Number of subjects: 0
Study 29552921 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged restraint (24-hour short-arm restraint device)
Number of subjects: 62
Study 29552921 — intervention group
Group type: COMPARATOR
Intervention: Manual restraint (intermittent holding restraint during therapy)
Number of subjects: 62
Study 29552921 — intervention group
Group type: COMPARATOR
Intervention: Comparison of prolonged restraint vs manual restraint
Number of subjects: 62
Study 26807637 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSA group (n = 24)
Number of subjects: 45
Study 26807637 — intervention group
Group type: COMPARATOR
Intervention: non-CUSA group (n = 21)
Number of subjects: 45
Study 24417482 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-framed message
Number of subjects: 115
Study 24417482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadness-framed message
Number of subjects: 115
Study 24417482 — intervention group
Group type: COMPARATOR
Intervention: No emotion-framed message
Number of subjects: 115
Study 22244160 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus intravenous bevacizumab (10 mg/kg IV every 14 days)
Number of subjects: 30
Study 22244160 — intervention group
Group type: COMPARATOR
Intervention: Observation (TACE-O)
Number of subjects: 30
Study 22244160 — intervention group
Group type: COMPARATOR
Intervention: TACE-O
Number of subjects: 30
Study 22244160 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-BEV
Number of subjects: 30
Study 19414843 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 17460134 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider Feedback
Number of subjects: 913
Study 17460134 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 913
Study 16022847 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg of ethinylestradiol and 100 microg of levonorgestrel
Number of subjects: 48
Study 16022847 — intervention group
Group type: COMPARATOR
Intervention: 30 microg of ethinylestradiol and 150 microg of levonorgestrel
Number of subjects: 48
Study 12243438 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 1.25 x 10(6) KIU aprotinin (4 doses)
Number of subjects: 97
Study 12243438 — intervention group
Group type: COMPARATOR
Intervention: Systemic application of 5 x 10(6) KIU aprotinin
Number of subjects: 97
Study 9951268 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of midazolam (mdz) using a nasal route
Number of subjects: 248
Study 9951268 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/kg of diazepam (dz) per os 45' before induction
Number of subjects: 248
Study 7616634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic plus para‐aortic irradiation
Number of subjects: 367
Study 7616634 — intervention group
Group type: COMPARATOR
Intervention: Pelvic only irradiation
Number of subjects: 367
Study 2340945 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg furosemide
Number of subjects: 0
Study 2340945 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 0
Study 2340945 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg flosequinan
Number of subjects: 0
Study 2340945 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg flosequinan
Number of subjects: 0
Study 6948488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injections of a mixture of corticosteroid and local anaesthetic, given once a week for three weeks.
Number of subjects: 33